Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | CAGR of 11.5%

Global Liquid Biopsy Market Size Worth USD25.24 Billion By 2032

According to a research report published by Spherical Insights & Consulting, The Global Liquid Biopsy Market Size is to Grow from USD 8.50 Billion in 2022 to USD 25.24 Billion By 2032, at a Compound Annual Growth Rate CAGR of 11.5% during the forecast period.

Browse key industry insights spread across 200 pages with 120 Market data tables and figures & charts from the report on the Global Liquid Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Technology (NGS, PCR, FISH, and Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, and Data Analysis), By Usage (RUO and Clinical), By Types of Sample (Blood, Urine, Saliva, and Cerebrospinal Fluid), By Circulating Biomarker (Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes & Extracellular Vesicles, and Others), By Products (Test/Services, Kits & Consumable, and Instruments), By Indication Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, and Others), By Clinical Application (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, and Diagnosis & Screening), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/liquid-biopsy-market

Liquid biopsy is a ground breaking non-invasive medical procedure that allows for early cancer identification and monitoring by analyzing numerous biomarkers found in a patient's blood or other bodily fluids. In contrast to conventional tissue biopsies, which can be invasive and limited by tumor accessibility, liquid biopsy provides a less hazardous and more accessible method of getting critical genetic and molecular information about tumors. Liquid biopsy gives information on a tumor's genetic mutations, therapy response, and potential for metastasis by identifying circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other biomolecules.

In 2022, the NGS segment accounted for around 52.8% market share

On the basis of the technology, the global liquid biopsy market is segmented into NGS, PCR, FISH, and others. The NGS (Next-Generation Sequencing) segment has held the largest market share in the liquid biopsy market due to its exceptional capabilities in detecting and analyzing genetic mutations and alterations. NGS offers high-throughput sequencing of circulating tumor DNA and other biomarkers, providing precise and comprehensive insights into cancer profiles. Its ability to handle multiple samples simultaneously and rapidly generate large amounts of genomic data has made NGS the preferred choice for liquid biopsy testing.

The blood segment held the largest market over the forecast period

Based on the sample type, the global liquid biopsy market is segmented into blood, urine, saliva, and cerebrospinal fluid. The blood segment dominated the liquid biopsy market over the forecast period primarily due to its non-invasive nature and ease of sample collection. Blood-based liquid biopsies offer a convenient and accessible method to detect and analyze circulating tumor cells (CTCs) and cell-free DNA (cfDNA), providing valuable information about cancer progression, treatment response, and genetic mutations.

The lung cancer segment held the largest revenue share of around 31.6% in 2022.

Based on the indication, the global liquid biopsy market is segmented into lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, and others. The lung cancer segment held the largest share in the liquid biopsy market owing to the high incidence and prevalence of lung cancer globally. Liquid biopsy offers a non-invasive and repeatable method for early detection, monitoring, and assessment of treatment response in lung cancer patients. The ability to analyze circulating tumor

The cell-free DNA segment is expected to grow at a significant CAGR of around 11.6% during the forecast period

Based on the circulating biomarker, the global liquid biopsy market is segmented into circulating tumor cells, cell-free DNA, circulating cell-free RNA, exosomes & extracellular vesicles, and others. The cell-free DNA (cfDNA) segment is anticipated to witness substantial growth in the liquid biopsy market due to its remarkable potential in cancer diagnosis and monitoring. cfDNA-based liquid biopsies allow the detection of tumor-specific genetic mutations and alterations, offering a non-invasive and real-time approach to track cancer progression and treatment response.

Asia-Pacific is predicted to grow at a fastest CAGR of around 11.7% over the projected period.

Based on region, Asia-Pacific is expected to experience the fastest growth in the liquid biopsy market during the forecast period, due to the rising prevalence of cancer, along with an aging population, which creates a significant demand for early detection and accurate monitoring solutions. Increasing investments in healthcare infrastructure and research capabilities have facilitated the adoption of advanced medical technologies, including liquid biopsy.

North America has emerged as a dominant player in the liquid biopsy market, holding the largest market share. The region benefits from a robust healthcare infrastructure and a high level of awareness about the importance of early cancer detection and personalized medicine. Significant investments in research and development, along with the presence of major biotechnology and pharmaceutical companies, have fostered the advancement of liquid biopsy technologies.

Some of the major players in the global liquid biopsy market include Bio-Rad Laboratories, Biocept Inc., Guardant Health, Illumina, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., and Thermo Fisher Scientific Inc.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global liquid biopsy market based on the below-mentioned segments:

Liquid Biopsy Market, By Technology

• NGS
• PCR
• FISH
• Others

Liquid Biopsy Market, By Workflow

• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis

Liquid Biopsy Market, By Usage

• RUO
• Clinical

Liquid Biopsy Market, By Type of Sample

• Blood
• Urine
• Saliva
• Cerebrospinal Fluid

Liquid Biopsy Market, By Circulating Biomarker

• Circulating Tumor Cells
• Cell-free DNA
• Circulating Cell-Free RNA
• Exosomes & Extracellular Vesicles
• Others

Liquid Biopsy Market, By Products

• Test/Services
• Kits & Consumable
• Instruments

Liquid Biopsy Market, By Indication Type

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Others

Liquid Biopsy Market, By Clinical Application

• Treatment Monitoring
• Prognosis & Recurrence Monitoring
• Treatment Selection
• Diagnosis & Screening

Liquid Biopsy Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter